Selected article for: "cell culture and essential role"
Author: Vuong, Wayne; Khan, Muhammad Bashir; Fischer, Conrad; Arutyunova, Elena; Lamer, Tess; Shields, Justin; Saffran, Holly A.; McKay, Ryan T.; van Belkum, Marco J.; Joyce, Michael A.; Young, Howard S.; Tyrrell, D. Lorne; Vederas, John C.; Lemieux, M. Joanne
Title: Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
  • Cord-id: zuc538yd
  • Document date: 2020_8_27
    • ID: zuc538yd
    Snippet: The main protease, M(pro) (or 3CL(pro)) in SARS-CoV-2 is a viable drug target because of its essential role in the cleavage of the virus polypeptide. Feline infectious peritonitis, a fatal coronavirus infection in cats, was successfully treated previously with a prodrug GC376, a dipeptide-based protease inhibitor. Here, we show the prodrug and its parent GC373, are effective inhibitors of the M(pro) from both SARS-CoV and SARS-CoV-2 with IC(50) values in the nanomolar range. Crystal structures o
    Document: The main protease, M(pro) (or 3CL(pro)) in SARS-CoV-2 is a viable drug target because of its essential role in the cleavage of the virus polypeptide. Feline infectious peritonitis, a fatal coronavirus infection in cats, was successfully treated previously with a prodrug GC376, a dipeptide-based protease inhibitor. Here, we show the prodrug and its parent GC373, are effective inhibitors of the M(pro) from both SARS-CoV and SARS-CoV-2 with IC(50) values in the nanomolar range. Crystal structures of SARS-CoV-2 M(pro) with these inhibitors have a covalent modification of the nucleophilic Cys145. NMR analysis reveals that inhibition proceeds via reversible formation of a hemithioacetal. GC373 and GC376 are potent inhibitors of SARS-CoV-2 replication in cell culture. They are strong drug candidates for the treatment of human coronavirus infections because they have already been successful in animals. The work here lays the framework for their use in human trials for the treatment of COVID-19.

    Search related documents:
    Co phrase search for related documents
    • acting antiviral and acute infection antiviral therapy: 1
    • acting antiviral and low bioavailability: 1
    • acting antiviral and lung epithelial: 1, 2
    • active site and acute infection: 1, 2, 3, 4, 5, 6
    • active site and acute toxicity: 1
    • active site and low bioavailability: 1, 2, 3
    • active site and low toxicity: 1, 2
    • active site and lung epithelial: 1, 2, 3, 4
    • acute infection and low bioavailability: 1, 2, 3
    • acute infection and low toxicity: 1, 2, 3
    • acute infection and lung epithelial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute infection and lysis buffer: 1
    • acute toxicity and low toxicity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute toxicity and lung epithelial: 1
    • acute toxicity and lysis buffer: 1
    • luminescence substrate and lysis buffer: 1, 2